On the 26th of November, Vall d’Hebron Institute of Research (VHIR), together with the "http://www.imi.europa.eu/" Innovative Medicine Initiative (IMI) held an Infoday. The main objective of this event was to show more in the details all the future call for proposals of the Public Private Partnership.To start with, Dr. Thomas Eichholtz, CSO and Corporate Director of R&D at Almirall, presented the dynamics behind EFPIA and the call for proposals). He was followed by Dr.Eva Molero, CEO at Synapse Research Management Partners, who gave the partipants more details about real IMI projects, and keys to successful participation and management of such projects. Dr. Marta Gomez Quintanilla, Spanish representative in IMI 2 from CDTI, showed the Spanish participation in IMI so far, and also insisted on the need to be more proactive, and participate more actively in future calls and projects.After the coffee break, Dr. Magda Gunn, from the IMI executive office, explained very clearly the rules and framework of IMI 2, giving tips on the dos and donts in the application process.Participants from different research institutes could discuss and exchange over the lunch break. Then, more insight on the future topics to come were given by Dr. Magda Gunn (IMI) together with Dr. Nima Behkami, Strategic Alliance director at MSD. Dr. Farid Bidgoli, MSD Real World Evidence Manager, also gave a bit more detail on the work they are currently carrying on.Finally, a specific session on venture capital closed the day. Dr. Rémi Droller, Managing partner at Kurma Partners, together with Dr. Nima Behkami led toward a discussion on the potential of future businesses supported by VC in the biomedical field.